Exploring the trajectory of quality-of-life deterioration associated with capecitabine-induced hand-foot syndrome and the optimal timing for rehabilitation intervention: secondary analysis of a randomized controlled trial

Objective To investigate the dynamic progression and key turning points of quality-of-life (QoL) impairment in patients with capecitabine-induced hand-foot syndrome (HFS) and identify the optimal timing for rehabilitation intervention. Methods This secondary analysis included 234 breast cancer patients receiving capecitabine from a multicenter, double-blind randomized controlled trial. HFS-related QoL (HF-QoL), EORTC QLQ-C30, and QLQ-BR23 were assessed longitudinally. Generalized estimating equations examined HFS grade-by-time interactions, and clinically significant deterioration was defined using the minimum clinically important difference (MCID ≥10 points). Results Significant HFS grade-by-time interactions were observed for HF-QoL (β=1.215, 95% CI = [0.689, 1.741], P < 0.001), QLQ-C30 (β=1.464, 95% CI = [0.820, 2.109], P < 0.001), and QLQ-BR23 (β=0.451, 95% CI = [0.148,0.753], P = 0.004), indicating accelerated QoL deterioration with increasing HFS severity. The proportion of patients with clinically significant HF-QoL deterioration increased sharply from Grade 1 to Grade 2 (18.9% vs. 41.9%; OR = 3.053, P = 0.010). Conclusion HFS severity and QoL deterioration show divergent trajectories; Grade 2 may represent a critical threshold at which QoL impairment crosses the threshold of clinical significance; progression from HFS Grade 1 to Grade 2 may be a potential time point for validation in future prospective rehabilitation intervention studies.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-12
DOI
https://doi.org/10.3389/fonc.2026.1988890
Primary Topic
Chemotherapy-related skin toxicity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploring the trajectory of quality-of-life deterioration associated with capecitabine-induced hand-foot syndrome and the optimal timing for rehabilitation intervention: secondary analysis of a randomized controlled trial

Yifan Lin, Jie Jia, Jie Zhang, Weilin Yin et al.
Frontiers in Oncology
Chemotherapy-related skin toxicity
article

Exploring the trajectory of quality-of-life deterioration associated with capecitabine-induced hand-foot syndrome and the optimal timing for rehabilitation intervention: secondary analysis of a randomized controlled trial

Yifan Lin, Jie Jia, Jie Zhang, Weilin Yin, Yujing Wang
article en

Abstract

Objective To investigate the dynamic progression and key turning points of quality-of-life (QoL) impairment in patients with capecitabine-induced hand-foot syndrome (HFS) and identify the optimal timing for rehabilitation intervention. Methods This secondary analysis included 234 breast cancer patients receiving capecitabine from a multicenter, double-blind randomized controlled trial. HFS-related QoL (HF-QoL), EORTC QLQ-C30, and QLQ-BR23 were assessed longitudinally. Generalized estimating equations examined HFS grade-by-time interactions, and clinically significant deterioration was defined using the minimum clinically important difference (MCID ≥10 points). Results Significant HFS grade-by-time interactions were observed for HF-QoL (β=1.215, 95% CI = [0.689, 1.741], P < 0.001), QLQ-C30 (β=1.464, 95% CI = [0.820, 2.109], P < 0.001), and QLQ-BR23 (β=0.451, 95% CI = [0.148,0.753], P = 0.004), indicating accelerated QoL deterioration with increasing HFS severity. The proportion of patients with clinically significant HF-QoL deterioration increased sharply from Grade 1 to Grade 2 (18.9% vs. 41.9%; OR = 3.053, P = 0.010). Conclusion HFS severity and QoL deterioration show divergent trajectories; Grade 2 may represent a critical threshold at which QoL impairment crosses the threshold of clinical significance; progression from HFS Grade 1 to Grade 2 may be a potential time point for validation in future prospective rehabilitation intervention studies.

Frontiers in OncologyVol. 16
Fujian Medical University (CN), First Affiliated Hospital of Fujian Medical University (CN)
Good health and well-being
Chemotherapy-related skin toxicity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon